NCT00979537View on ClinicalTrials.gov

Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Healthy
Interventions
DRUG

Nisoldipine Extended-release Tablets, 40 mg

DRUG

Sular Tablets, 40 mg

Trial Locations (1)

58104

Pracs Institute, Ltd, Fargo

Sponsors
All Listed Sponsors
lead

Mylan Pharmaceuticals Inc

INDUSTRY

NCT00979537 - Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers | Biotech Hunter | Biotech Hunter